메뉴 건너뛰기




Volumn 63, Issue 2 SUPPL.2, 2014, Pages

Glycemic management in ESRD and earlier stages of CKD

Author keywords

Chronic kidney disease (CKD); diabetes mellitus; end stage renal disease (ESRD); hemoglobin A1c (HbA1c); hyperglycemia

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; AMYLIN; ANTIDIABETIC AGENT; BIGUANIDE DERIVATIVE; BILE ACID SEQUESTRANT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DOPAMINE 2 RECEPTOR STIMULATING AGENT; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; HEMOGLOBIN A1C; INSULIN; MEGLITINIDE; SODIUM GLUCOSE COTRANSPORTER 2; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA; UNCLASSIFIED DRUG;

EID: 84892923794     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2013.10.049     Document Type: Article
Times cited : (76)

References (134)
  • 1
    • 0033631547 scopus 로고    scopus 로고
    • Impact of end-stage renal disease and dialysis on glycemic control
    • R.H. Mak Impact of end-stage renal disease and dialysis on glycemic control Semin Dial 13 1 2000 4 8
    • (2000) Semin Dial , vol.13 , Issue.1 , pp. 4-8
    • Mak, R.H.1
  • 2
    • 0021920713 scopus 로고
    • Role of parathyroid hormone in the glucose intolerance of chronic renal failure
    • M. Akmal, S.G. Massry, D.A. Goldstein, P. Fanti, A. Weisz, and R.A. DeFronzo Role of parathyroid hormone in the glucose intolerance of chronic renal failure J Clin Invest 75 3 1985 1037 1044 (Pubitemid 15115274)
    • (1985) Journal of Clinical Investigation , vol.75 , Issue.3 , pp. 1037-1044
    • Akmal, M.1    Massry, S.G.2    Goldstein, D.A.3
  • 3
    • 0026523822 scopus 로고
    • Intravenous 1,25 dihydroxycholecalciferol corrects glucose intolerance in hemodialysis patients
    • R.H. Mak Intravenous 1,25 dihydroxycholecalciferol corrects glucose intolerance in hemodialysis patients Kidney Int 41 4 1992 1049 1054
    • (1992) Kidney Int , vol.41 , Issue.4 , pp. 1049-1054
    • Mak, R.H.1
  • 4
    • 0030665213 scopus 로고    scopus 로고
    • Carbohydrate and insulin metabolism in renal failure
    • A. Alvestrand Carbohydrate and insulin metabolism in renal failure Kidney Int Suppl 36 1997 S48 S52
    • (1997) Kidney Int Suppl , vol.36
    • Alvestrand, A.1
  • 5
    • 12744279326 scopus 로고    scopus 로고
    • Redox paradox: Insulin action is facilitated by insulin-stimulated reactive oxygen species with multiple potential signaling targets
    • B.J. Goldstein, K. Mahadev, and X. Wu Redox paradox: insulin action is facilitated by insulin-stimulated reactive oxygen species with multiple potential signaling targets Diabetes 54 2 2005 311 321
    • (2005) Diabetes , vol.54 , Issue.2 , pp. 311-321
    • Goldstein, B.J.1    Mahadev, K.2    Wu, X.3
  • 6
    • 79953253731 scopus 로고    scopus 로고
    • Tracing the footsteps of glomerular insulin signaling in diabetic kidney disease
    • G.Y. Chang, A.S. Park, and K. Susztak Tracing the footsteps of glomerular insulin signaling in diabetic kidney disease Kidney Int 79 8 2011 802 804
    • (2011) Kidney Int , vol.79 , Issue.8 , pp. 802-804
    • Chang, G.Y.1    Park, A.S.2    Susztak, K.3
  • 8
    • 0019984476 scopus 로고
    • Insulin resistance in uremia mediated by postbinding defects
    • D. Smith, and R.A. DeFronzo Insulin resistance in uremia mediated by postbinding defects Kidney Int 22 1 1982 54 62 (Pubitemid 12091218)
    • (1982) Kidney International , vol.22 , Issue.1 , pp. 54-62
    • Smith, D.1    DeFronzo, R.A.2
  • 9
    • 0026792995 scopus 로고
    • Glucose homeostasis and the kidney
    • H.J. Adrogue Glucose homeostasis and the kidney Kidney Int 42 5 1992 1266 1282
    • (1992) Kidney Int , vol.42 , Issue.5 , pp. 1266-1282
    • Adrogue, H.J.1
  • 10
    • 0025976578 scopus 로고
    • Enhanced insulin sensitivity in extrarenal potassium handling in uremic rats
    • I.A. Goecke, S. Bonilla, E.T. Marusic, and M. Alvo Enhanced insulin sensitivity in extrarenal potassium handling in uremic rats Kidney Int 39 1 1991 39 43
    • (1991) Kidney Int , vol.39 , Issue.1 , pp. 39-43
    • Goecke, I.A.1    Bonilla, S.2    Marusic, E.T.3    Alvo, M.4
  • 11
    • 0018140320 scopus 로고
    • Glucose intolerance in uremia. Quantification of pancreatic beta cell sensitivity to glucose and tissue sensitivity to insulin
    • R.A. DeFronzo, J.D. Tobin, J.W. Rowe, and R. Andres Glucose intolerance in uremia. Quantification of pancreatic beta cell sensitivity to glucose and tissue sensitivity to insulin J Clin Invest 62 2 1978 425 435 (Pubitemid 8393313)
    • (1978) Journal of Clinical Investigation , vol.62 , Issue.2 , pp. 425-435
    • DeFronzo, R.A.1    Tobin, J.D.2    Rowe, J.W.3    Andres, R.4
  • 12
    • 0022384705 scopus 로고
    • Insulin-mediated glucose uptake in nondialyzed and dialyzed uremic insulin-dependent diabetic subjects
    • O. Schmitz Insulin-mediated glucose uptake in nondialyzed and dialyzed uremic insulin-dependent diabetic subjects Diabetes 34 11 1985 1152 1159 (Pubitemid 16218520)
    • (1985) Diabetes , vol.34 , Issue.11 , pp. 1152-1159
    • Schmitz, O.1
  • 13
    • 54049130793 scopus 로고    scopus 로고
    • Review article: The role of adipose tissue in uraemia-related insulin resistance
    • B. Manolescu, I. Stoian, V. Atanasiu, C. Busu, and O. Lupescu Review article: the role of adipose tissue in uraemia-related insulin resistance Nephrology (Carlton) 13 7 2008 622 628
    • (2008) Nephrology (Carlton) , vol.13 , Issue.7 , pp. 622-628
    • Manolescu, B.1    Stoian, I.2    Atanasiu, V.3    Busu, C.4    Lupescu, O.5
  • 14
    • 67651097807 scopus 로고    scopus 로고
    • Adiponectin is positively associated with insulin resistance in subjects with type 2 diabetic nephropathy and effects of angiotensin II type 1 receptor blocker losartan
    • L.L. Guo, Y. Pan, and H.M. Jin Adiponectin is positively associated with insulin resistance in subjects with type 2 diabetic nephropathy and effects of angiotensin II type 1 receptor blocker losartan Nephrol Dial Transplant 24 6 2009 1876 1883
    • (2009) Nephrol Dial Transplant , vol.24 , Issue.6 , pp. 1876-1883
    • Guo, L.L.1    Pan, Y.2    Jin, H.M.3
  • 15
    • 37149054939 scopus 로고    scopus 로고
    • Inflammation and Insulin Resistance in Uremia
    • DOI 10.1053/j.jrn.2007.10.015, PII S1051227607002336
    • M. Zanetti, R. Barazzoni, and G. Guarnieri Inflammation and insulin resistance in uremia J Ren Nutr 18 1 2008 70 75 (Pubitemid 350258685)
    • (2008) Journal of Renal Nutrition , vol.18 , Issue.1 , pp. 70-75
    • Zanetti, M.1    Barazzoni, R.2    Guarnieri, G.3
  • 16
    • 69249171375 scopus 로고    scopus 로고
    • Effect of recombinant human erythropoietin on insulin resistance in hemodialysis patients
    • E. Khedr, M. El-Sharkawy, and S. Abdulwahab et al. Effect of recombinant human erythropoietin on insulin resistance in hemodialysis patients Hemodial Int 13 3 2009 340 346
    • (2009) Hemodial Int , vol.13 , Issue.3 , pp. 340-346
    • Khedr, E.1    El-Sharkawy, M.2    Abdulwahab, S.3
  • 17
    • 77955249418 scopus 로고    scopus 로고
    • Insulin resistance and protein energy metabolism in patients with advanced chronic kidney disease
    • E.D. Siew, and T.A. Ikizler Insulin resistance and protein energy metabolism in patients with advanced chronic kidney disease Semin Dial 23 4 2010 378 382
    • (2010) Semin Dial , vol.23 , Issue.4 , pp. 378-382
    • Siew, E.D.1    Ikizler, T.A.2
  • 18
    • 33845804760 scopus 로고    scopus 로고
    • Effects of Glucose Homeostasis on Protein Metabolism in Patients With Advanced Chronic Kidney Disease
    • DOI 10.1053/j.jrn.2006.10.004, PII S1051227606002305, Proceedings from the XIII International Congress on Nutrition and Metabolism in Renal Disease
    • T.A. Ikizler Effects of glucose homeostasis on protein metabolism in patients with advanced chronic kidney disease J Ren Nutr 17 1 2007 13 16 (Pubitemid 46014450)
    • (2007) Journal of Renal Nutrition , vol.17 , Issue.1 , pp. 13-16
    • Ikizler, T.A.1
  • 20
    • 33846185124 scopus 로고    scopus 로고
    • Insulin resistance is associated with skeletal muscle protein breakdown in non-diabetic chronic hemodialysis patients
    • DOI 10.1038/sj.ki.5001984, PII 5001984
    • E.D. Siew, L.B. Pupim, K.M. Majchrzak, A. Shintani, P.J. Flakoll, and T.A. Ikizler Insulin resistance is associated with skeletal muscle protein breakdown in non-diabetic chronic hemodialysis patients Kidney Int 71 2 2007 146 152 (Pubitemid 46094688)
    • (2007) Kidney International , vol.71 , Issue.2 , pp. 146-152
    • Siew, E.D.1    Pupim, L.B.2    Majchrzak, K.M.3    Shintani, A.4    Flakoll, P.J.5    Ikizler, T.A.6
  • 21
    • 78049301082 scopus 로고    scopus 로고
    • Insulin resistance at different stages of diabetic kidney disease in India
    • V. Viswanathan, P. Tilak, R. Meerza, and S. Kumpatla Insulin resistance at different stages of diabetic kidney disease in India J Assoc Physicians India 58 2010 612 615
    • (2010) J Assoc Physicians India , vol.58 , pp. 612-615
    • Viswanathan, V.1    Tilak, P.2    Meerza, R.3    Kumpatla, S.4
  • 23
    • 79953241079 scopus 로고    scopus 로고
    • Glomerular-specific protein kinase C-beta-induced insulin receptor substrate-1 dysfunction and insulin resistance in rat models of diabetes and obesity
    • A. Mima, Y. Ohshiro, and M. Kitada et al. Glomerular-specific protein kinase C-beta-induced insulin receptor substrate-1 dysfunction and insulin resistance in rat models of diabetes and obesity Kidney Int 79 8 2011 883 896
    • (2011) Kidney Int , vol.79 , Issue.8 , pp. 883-896
    • Mima, A.1    Ohshiro, Y.2    Kitada, M.3
  • 24
  • 25
    • 79952221451 scopus 로고    scopus 로고
    • Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans
    • J.F. List, and J.M. Whaley Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans Kidney Int Suppl 120 2011 S20 S27
    • (2011) Kidney Int Suppl , vol.120
    • List, J.F.1    Whaley, J.M.2
  • 26
    • 79952404360 scopus 로고    scopus 로고
    • SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function
    • M.J. Jurczak, H.Y. Lee, and A.L. Birkenfeld et al. SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function Diabetes 60 3 2011 890 898
    • (2011) Diabetes , vol.60 , Issue.3 , pp. 890-898
    • Jurczak, M.J.1    Lee, H.Y.2    Birkenfeld, A.L.3
  • 27
    • 77956656798 scopus 로고    scopus 로고
    • The kidneys as an emerging target for the treatment of diabetes mellitus: What we know, thought we knew and hope to gain
    • M.H. Ahmed The kidneys as an emerging target for the treatment of diabetes mellitus: what we know, thought we knew and hope to gain Int J Diabetes Mellitus 2 2 2010 125 126
    • (2010) Int J Diabetes Mellitus , vol.2 , Issue.2 , pp. 125-126
    • Ahmed, M.H.1
  • 28
    • 84886829422 scopus 로고    scopus 로고
    • Canagliflozin approved for type 2 diabetes
    • K. Traynor Canagliflozin approved for type 2 diabetes Am J Health Syst Pharm 70 10 2013 834
    • (2013) Am J Health Syst Pharm , vol.70 , Issue.10 , pp. 834
    • Traynor, K.1
  • 29
    • 84865479822 scopus 로고    scopus 로고
    • Why do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans?
    • J.J. Liu, T. Lee, and R.A. Defronzo Why do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans? Diabetes 61 9 2012 2199 2204
    • (2012) Diabetes , vol.61 , Issue.9 , pp. 2199-2204
    • Liu, J.J.1    Lee, T.2    Defronzo, R.A.3
  • 30
    • 84885171560 scopus 로고    scopus 로고
    • The clinical efficacy and safety of sodium glucose cotransporter-2 inhibitors in adults with type 2 diabetes mellitus
    • S. Riser Taylor, and K.B. Harris The clinical efficacy and safety of sodium glucose cotransporter-2 inhibitors in adults with type 2 diabetes mellitus Pharmacotherapy 33 9 2013 984 999
    • (2013) Pharmacotherapy , vol.33 , Issue.9 , pp. 984-999
    • Riser Taylor, S.1    Harris, K.B.2
  • 31
    • 84866268783 scopus 로고    scopus 로고
    • Management of hyperglycemia in type 2 diabetes: A patient-centered approach: Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
    • S.E. Inzucchi, R.M. Bergenstal, and J.B. Buse et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care 35 6 2012 1364 1379
    • (2012) Diabetes Care , vol.35 , Issue.6 , pp. 1364-1379
    • Inzucchi, S.E.1    Bergenstal, R.M.2    Buse, J.B.3
  • 33
    • 33845760213 scopus 로고    scopus 로고
    • KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease
    • National Kidney Foundation
    • National Kidney Foundation KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease Am J Kidney Dis 49 2 suppl 2 2007 S12 S154
    • (2007) Am J Kidney Dis , vol.49 , Issue.2 SUPPL. 2
  • 34
    • 0036482285 scopus 로고    scopus 로고
    • 1c in the Diabetes Control and Complications Trial
    • DOI 10.2337/diacare.25.2.275
    • C.L. Rohlfing, H.M. Wiedmeyer, R.R. Little, J.D. England, A. Tennill, and D.E. Goldstein Defining the relationship between plasma glucose and HbA(1c): analysis of glucose profiles and HbA(1c) in the Diabetes Control and Complications Trial Diabetes Care 25 2 2002 275 278 (Pubitemid 41079621)
    • (2002) Diabetes Care , vol.25 , Issue.2 , pp. 275-278
    • Rohlfing, C.L.1    Wiedmeyer, H.-M.2    Little, R.R.3    England, J.D.4    Tennill, A.5    Goldstein, D.E.6
  • 36
    • 82455174130 scopus 로고    scopus 로고
    • Association between glycemic control and adverse outcomes in people with diabetes mellitus and chronic kidney disease: A population-based cohort study
    • S. Shurraw, B. Hemmelgarn, and M. Lin et al. Association between glycemic control and adverse outcomes in people with diabetes mellitus and chronic kidney disease: a population-based cohort study Arch Intern Med 171 21 2011 1920 1927
    • (2011) Arch Intern Med , vol.171 , Issue.21 , pp. 1920-1927
    • Shurraw, S.1    Hemmelgarn, B.2    Lin, M.3
  • 37
    • 79957824748 scopus 로고    scopus 로고
    • Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy
    • J.M. Lachin, G. Viberti, and B. Zinman et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy Clin J Am Soc Nephrol 6 5 2011 1032 1040
    • (2011) Clin J Am Soc Nephrol , vol.6 , Issue.5 , pp. 1032-1040
    • Lachin, J.M.1    Viberti, G.2    Zinman, B.3
  • 40
    • 79952599949 scopus 로고    scopus 로고
    • Reexamining metrics for glucose control
    • K.B. Rubinow, and I.B. Hirsch Reexamining metrics for glucose control JAMA 305 11 2011 1132 1133
    • (2011) JAMA , vol.305 , Issue.11 , pp. 1132-1133
    • Rubinow, K.B.1    Hirsch, I.B.2
  • 41
    • 3142662783 scopus 로고    scopus 로고
    • Time to move beyond glycosylated haemoglobin
    • DOI 10.1111/j.1464-5491.2004.01318.x
    • R.I. Holt, and I. Gallen Time to move beyond glycosylated haemoglobin Diabet Med 21 7 2004 655 656 (Pubitemid 38916207)
    • (2004) Diabetic Medicine , vol.21 , Issue.7 , pp. 655-656
    • Holt, R.I.G.1    Gallent, I.2
  • 43
    • 60149110364 scopus 로고    scopus 로고
    • US Renal Data System National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases Bethesda, MD
    • US Renal Data System USRDS 2008 Annual Data Report: Atlas of End-Stage Renal Disease in the United States 2008 National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases Bethesda, MD
    • (2008) USRDS 2008 Annual Data Report: Atlas of End-Stage Renal Disease in the United States
  • 44
    • 84871310537 scopus 로고    scopus 로고
    • US Renal Data System 2012 annual data report
    • e1-e476
    • A.J. Collins, R.N. Foley, and C. Herzog et al. US Renal Data System 2012 annual data report Am J Kidney Dis 61 1 suppl 1 2013 A7 e1-e476
    • (2013) Am J Kidney Dis , vol.61 , Issue.1 SUPPL. 1 , pp. 7
    • Collins, A.J.1    Foley, R.N.2    Herzog, C.3
  • 45
    • 33749534536 scopus 로고    scopus 로고
    • Hemodialyzed type I and type II diabetic patients in the US: Characteristics, glycemic control, and survival
    • DOI 10.1038/sj.ki.5001789, PII 5001789
    • M.E. Williams, E. Lacson Jr., M. Teng, N. Ofsthun, and J.M. Lazarus Hemodialyzed type I and type II diabetic patients in the US: characteristics, glycemic control, and survival Kidney Int 70 8 2006 1503 1509 (Pubitemid 44527322)
    • (2006) Kidney International , vol.70 , Issue.8 , pp. 1503-1509
    • Williams, M.E.1    Lacson Jr., E.2    Teng, M.3    Ofsthun, N.4    Lazarus, J.M.5
  • 46
    • 4544315738 scopus 로고    scopus 로고
    • Red blood cell survival in chronic renal failure
    • DOI 10.1053/j.ajkd.2004.06.018, PII S0272638604009515
    • J. Ly, R. Marticorena, and S. Donnelly Red blood cell survival in chronic renal failure Am J Kidney Dis 44 4 2004 715 719 (Pubitemid 39237616)
    • (2004) American Journal of Kidney Diseases , vol.44 , Issue.4 , pp. 715-719
    • Ly, J.1    Marticorena, R.2    Donnelly, S.3
  • 48
    • 64849098665 scopus 로고    scopus 로고
    • Class effect of erythropoietin therapy on hemoglobin A(1c) in a patient with diabetes mellitus and chronic kidney disease not undergoing hemodialysis
    • J.N. Brown, D.W. Kemp, and K.R. Brice Class effect of erythropoietin therapy on hemoglobin A(1c) in a patient with diabetes mellitus and chronic kidney disease not undergoing hemodialysis Pharmacotherapy 29 4 2009 468 472
    • (2009) Pharmacotherapy , vol.29 , Issue.4 , pp. 468-472
    • Brown, J.N.1    Kemp, D.W.2    Brice, K.R.3
  • 50
    • 77951626611 scopus 로고    scopus 로고
    • Hemoglobin A(1c) and fructosamine for assessing glycemic control in diabetic patients with CKD stages 3 and 4
    • H.S. Chen, T.E. Wu, and H.D. Lin et al. Hemoglobin A(1c) and fructosamine for assessing glycemic control in diabetic patients with CKD stages 3 and 4 Am J Kidney Dis 55 5 2010 867 874
    • (2010) Am J Kidney Dis , vol.55 , Issue.5 , pp. 867-874
    • Chen, H.S.1    Wu, T.E.2    Lin, H.D.3
  • 51
    • 69249098196 scopus 로고    scopus 로고
    • Glycaemic control in type 2 diabetic patients on chronic haemodialysis: Use of a continuous glucose monitoring system
    • J.P. Riveline, J. Teynie, and S. Belmouaz et al. Glycaemic control in type 2 diabetic patients on chronic haemodialysis: use of a continuous glucose monitoring system Nephrol Dial Transplant 24 9 2009 2866 2871
    • (2009) Nephrol Dial Transplant , vol.24 , Issue.9 , pp. 2866-2871
    • Riveline, J.P.1    Teynie, J.2    Belmouaz, S.3
  • 53
    • 77957315885 scopus 로고    scopus 로고
    • Glycemic control and extended hemodialysis survival in patients with diabetes mellitus: Comparative results of traditional and time-dependent Cox model analyses
    • M.E. Williams, E. Lacson Jr., W. Wang, J.M. Lazarus, and R. Hakim Glycemic control and extended hemodialysis survival in patients with diabetes mellitus: comparative results of traditional and time-dependent Cox model analyses Clin J Am Soc Nephrol 5 9 2010 1595 1601
    • (2010) Clin J Am Soc Nephrol , vol.5 , Issue.9 , pp. 1595-1601
    • Williams, M.E.1    Lacson, Jr.E.2    Wang, W.3    Lazarus, J.M.4    Hakim, R.5
  • 54
    • 77957306703 scopus 로고    scopus 로고
    • 1c in hemodialysis patients: Should one size fit all?
    • 1c in hemodialysis patients: should one size fit all? Clin J Am Soc Nephrol 5 9 2010 1539 1541
    • (2010) Clin J Am Soc Nephrol , vol.5 , Issue.9 , pp. 1539-1541
    • Ix, J.H.1
  • 55
    • 84869857901 scopus 로고    scopus 로고
    • Hemoglobin A(1c) levels and mortality in the diabetic hemodialysis population: Findings from the Dialysis Outcomes and Practice Patterns Study (DOPPS)
    • S.P. Ramirez, K.P. McCullough, and J.R. Thumma et al. Hemoglobin A(1c) levels and mortality in the diabetic hemodialysis population: findings from the Dialysis Outcomes and Practice Patterns Study (DOPPS) Diabetes Care 35 12 2012 2527 2532
    • (2012) Diabetes Care , vol.35 , Issue.12 , pp. 2527-2532
    • Ramirez, S.P.1    McCullough, K.P.2    Thumma, J.R.3
  • 56
    • 73349126712 scopus 로고    scopus 로고
    • Glycemic control and cardiovascular events in diabetic hemodialysis patients
    • C. Drechsler, V. Krane, E. Ritz, W. Marz, and C. Wanner Glycemic control and cardiovascular events in diabetic hemodialysis patients Circulation 120 24 2009 2421 2428
    • (2009) Circulation , vol.120 , Issue.24 , pp. 2421-2428
    • Drechsler, C.1    Krane, V.2    Ritz, E.3    Marz, W.4    Wanner, C.5
  • 57
    • 0037373850 scopus 로고    scopus 로고
    • Assessing glycemic control in patients with diabetes and end-stage renal failure
    • DOI 10.1053/ajkd.2003.50114
    • A. Ansari, S. Thomas, and D. Goldsmith Assessing glycemic control in patients with diabetes and end-stage renal failure Am J Kidney Dis 41 3 2003 523 531 (Pubitemid 36278368)
    • (2003) American Journal of Kidney Diseases , vol.41 , Issue.3 , pp. 523-531
    • Ansari, A.1    Thomas, S.2    Goldsmith, D.3
  • 58
    • 77955156159 scopus 로고    scopus 로고
    • Serum fructosamine versus glycosylated hemoglobin as an index of glycemic control, hospitalization, and infection in diabetic hemodialysis patients
    • N. Mittman, B. Desiraju, and I. Fazil et al. Serum fructosamine versus glycosylated hemoglobin as an index of glycemic control, hospitalization, and infection in diabetic hemodialysis patients Kidney Int Suppl 117 2010 S41 S45
    • (2010) Kidney Int Suppl , vol.117
    • Mittman, N.1    Desiraju, B.2    Fazil, I.3
  • 59
    • 84865503843 scopus 로고    scopus 로고
    • A pharmacokinetic model for the glycation of albumin
    • O. Alskar, J. Korell, and S.B. Duffull A pharmacokinetic model for the glycation of albumin J Pharmacokinet Pharmacodyn 39 3 2012 273 282
    • (2012) J Pharmacokinet Pharmacodyn , vol.39 , Issue.3 , pp. 273-282
    • Alskar, O.1    Korell, J.2    Duffull, S.B.3
  • 60
    • 50249186315 scopus 로고    scopus 로고
    • Glycated hemoglobin or glycated albumin for assessment of glycemic control in hemodialysis patients with diabetes?
    • M. Abe, and K. Matsumoto Glycated hemoglobin or glycated albumin for assessment of glycemic control in hemodialysis patients with diabetes? Nat Clin Pract Nephrol 4 9 2008 482 483
    • (2008) Nat Clin Pract Nephrol , vol.4 , Issue.9 , pp. 482-483
    • Abe, M.1    Matsumoto, K.2
  • 62
    • 79960311683 scopus 로고    scopus 로고
    • Glycated albumin and risk of death and hospitalizations in diabetic dialysis patients
    • B.I. Freedman, L. Andries, and Z.K. Shihabi et al. Glycated albumin and risk of death and hospitalizations in diabetic dialysis patients Clin J Am Soc Nephrol 6 7 2011 1635 1643
    • (2011) Clin J Am Soc Nephrol , vol.6 , Issue.7 , pp. 1635-1643
    • Freedman, B.I.1    Andries, L.2    Shihabi, Z.K.3
  • 63
    • 84859095662 scopus 로고    scopus 로고
    • Serum 1,5-anhydroglucitol concentrations are a reliable index of glycemic control in type 2 diabetes with mild or moderate renal dysfunction
    • W.J. Kim, C.Y. Park, and K.B. Lee et al. Serum 1,5-anhydroglucitol concentrations are a reliable index of glycemic control in type 2 diabetes with mild or moderate renal dysfunction Diabetes Care 35 2 2012 281 286
    • (2012) Diabetes Care , vol.35 , Issue.2 , pp. 281-286
    • Kim, W.J.1    Park, C.Y.2    Lee, K.B.3
  • 65
    • 79251591619 scopus 로고    scopus 로고
    • Similar outcomes with hemodialysis and peritoneal dialysis in patients with end-stage renal disease
    • R. Mehrotra, Y.W. Chiu, K. Kalantar-Zadeh, J. Bargman, and E. Vonesh Similar outcomes with hemodialysis and peritoneal dialysis in patients with end-stage renal disease Arch Intern Med 171 2 2011 110 118
    • (2011) Arch Intern Med , vol.171 , Issue.2 , pp. 110-118
    • Mehrotra, R.1    Chiu, Y.W.2    Kalantar-Zadeh, K.3    Bargman, J.4    Vonesh, E.5
  • 67
    • 0346881199 scopus 로고    scopus 로고
    • Renal replacement therapy in patients with diabetes and end-stage renal disease
    • F. Locatelli, P. Pozzoni, and L. Del Vecchio Renal replacement therapy in patients with diabetes and end-stage renal disease J Am Soc Nephrol 15 suppl 1 2004 S25 S29
    • (2004) J Am Soc Nephrol , vol.15 , Issue.SUPPL. 1
    • Locatelli, F.1    Pozzoni, P.2    Del Vecchio, L.3
  • 68
    • 77950937491 scopus 로고    scopus 로고
    • Biocompatible peritoneal dialysis solutions: Do we have one?
    • K. Chaudhary, and R. Khanna Biocompatible peritoneal dialysis solutions: do we have one? Clin J Am Soc Nephrol 5 4 2010 723 732
    • (2010) Clin J Am Soc Nephrol , vol.5 , Issue.4 , pp. 723-732
    • Chaudhary, K.1    Khanna, R.2
  • 69
    • 0035656524 scopus 로고    scopus 로고
    • Insulin therapy during peritoneal dialysis: Pros and cons of various forms of administration
    • E. Quellhorst Insulin therapy during peritoneal dialysis: pros and cons of various forms of administration J Am Soc Nephrol 13 suppl 1 2002 S92 S96
    • (2002) J Am Soc Nephrol , vol.13 , Issue.SUPPL. 1
    • Quellhorst, E.1
  • 70
    • 0141797504 scopus 로고    scopus 로고
    • Lesson of the week: Spurious hyperglycaemia and icodextrin in peritoneal dialysis fluid
    • S.G. Riley, J. Chess, K.L. Donovan, and J.D. Williams Spurious hyperglycaemia and icodextrin in peritoneal dialysis fluid BMJ 327 7415 2003 608 609 (Pubitemid 37115116)
    • (2003) British Medical Journal , vol.327 , Issue.7415 , pp. 608-609
    • Riley, S.G.1    Chess, J.2    Donovan, K.L.3    Williams, J.D.4
  • 71
    • 84855185039 scopus 로고    scopus 로고
    • Standards of medical care in diabetes - 2012
    • American Diabetes Association
    • American Diabetes Association Standards of medical care in diabetes - 2012 Diabetes Care 35 suppl 1 2012 S11 S63
    • (2012) Diabetes Care , vol.35 , Issue.SUPPL. 1
  • 72
    • 40049106685 scopus 로고    scopus 로고
    • Hypoglycaemia in Type 2 diabetes
    • DOI 10.1111/j.1464-5491.2007.02341.x
    • S.A. Amiel, T. Dixon, R. Mann, and K. Jameson Hypoglycaemia in type 2 diabetes Diabet Med 25 3 2008 245 254 (Pubitemid 351322690)
    • (2008) Diabetic Medicine , vol.25 , Issue.3 , pp. 245-254
    • Amiel, S.A.1    Dixon, T.2    Mann, R.3    Jameson, K.4
  • 73
    • 79952207468 scopus 로고    scopus 로고
    • Frequent hypoglycemia among elderly patients with poor glycemic control
    • M.N. Munshi, A.R. Segal, and E. Suhl et al. Frequent hypoglycemia among elderly patients with poor glycemic control Arch Intern Med 171 4 2011 362 364
    • (2011) Arch Intern Med , vol.171 , Issue.4 , pp. 362-364
    • Munshi, M.N.1    Segal, A.R.2    Suhl, E.3
  • 76
    • 58149389215 scopus 로고    scopus 로고
    • Glucose control and vascular complications in veterans with type 2 diabetes
    • W. Duckworth, C. Abraira, and T. Moritz et al. Glucose control and vascular complications in veterans with type 2 diabetes N Engl J Med 360 2 2009 129 139
    • (2009) N Engl J Med , vol.360 , Issue.2 , pp. 129-139
    • Duckworth, W.1    Abraira, C.2    Moritz, T.3
  • 77
    • 0008014591 scopus 로고
    • Carbohydrate metabolism in end-stage renal disease
    • S.K. Mujais, and G. Fadda Carbohydrate metabolism in end-stage renal disease Semin Dial 2 1989 46 53
    • (1989) Semin Dial , vol.2 , pp. 46-53
    • Mujais, S.K.1    Fadda, G.2
  • 78
    • 0034055364 scopus 로고    scopus 로고
    • Hypoglycemia in patients with renal failure
    • DOI 10.1081/JDI-100100866
    • Y.S. Haviv, M. Sharkia, and R. Safadi Hypoglycemia in patients with renal failure Ren Fail 22 2 2000 219 223 (Pubitemid 30243986)
    • (2000) Renal Failure , vol.22 , Issue.2 , pp. 219-223
    • Haviv, Y.S.1    Sharkia, M.2    Safadi, R.3
  • 79
    • 63349083389 scopus 로고    scopus 로고
    • Hypoglycemia in diabetic patients undergoing chronic hemodialysis
    • C.Y. Sun, C.C. Lee, and M.S. Wu Hypoglycemia in diabetic patients undergoing chronic hemodialysis Ther Apher Dial 13 2 2009 95 102
    • (2009) Ther Apher Dial , vol.13 , Issue.2 , pp. 95-102
    • Sun, C.Y.1    Lee, C.C.2    Wu, M.S.3
  • 80
    • 77957318240 scopus 로고    scopus 로고
    • High glucose variability increases risk of all-cause and hypoglycemia-related hospitalization in diabetic chronic hemodialysis patients [abstract TH-PO349]
    • M.E. Williams, E. Lacson Jr., and W. Wang High glucose variability increases risk of all-cause and hypoglycemia-related hospitalization in diabetic chronic hemodialysis patients [abstract TH-PO349] J Am Soc Nephrol 20 2009 193A
    • (2009) J Am Soc Nephrol , vol.20
    • Williams, M.E.1    Lacson, Jr.E.2    Wang, W.3
  • 81
    • 49649114691 scopus 로고    scopus 로고
    • Levofloxacin-associated hypoglycaemia complicated by pontine myelinolysis and quadriplegia
    • S. Vallurupalli, G. Huesmann, J. Gregory, and M.G. Jakoby Levofloxacin-associated hypoglycaemia complicated by pontine myelinolysis and quadriplegia Diabet Med 25 7 2008 856 859
    • (2008) Diabet Med , vol.25 , Issue.7 , pp. 856-859
    • Vallurupalli, S.1    Huesmann, G.2    Gregory, J.3    Jakoby, M.G.4
  • 82
    • 79551673658 scopus 로고    scopus 로고
    • Strategies for optimizing glycemic control and cardiovascular prognosis in patients with type 2 diabetes mellitus
    • J.H. O'Keefe, M. Abuannadi, C.J. Lavie, and D.S. Bell Strategies for optimizing glycemic control and cardiovascular prognosis in patients with type 2 diabetes mellitus Mayo Clin Proc 86 2 2011 128 138
    • (2011) Mayo Clin Proc , vol.86 , Issue.2 , pp. 128-138
    • O'Keefe, J.H.1    Abuannadi, M.2    Lavie, C.J.3    Bell, D.S.4
  • 83
    • 84856751751 scopus 로고    scopus 로고
    • 1c levels with vascular complications and death in patients with type 2 diabetes: Evidence of glycaemic thresholds
    • 1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds Diabetologia 55 3 2012 636 643
    • (2012) Diabetologia , vol.55 , Issue.3 , pp. 636-643
    • Zoungas, S.1    Chalmers, J.2    Ninomiya, T.3
  • 84
    • 0035349026 scopus 로고    scopus 로고
    • Impact of Diabetic Nephropathy on Pharmacodynamic and Pharmacokinetic Properties of Insulin in Type 1 Diabetic Patients
    • K. Rave, T. Heise, A. Pfutzner, L. Heinemann, and P.T. Sawicki Impact of diabetic nephropathy on pharmacodynamic and pharmacokinetic properties of insulin in type 1 diabetic patients Diabetes Care 24 5 2001 886 890 (Pubitemid 33636064)
    • (2001) Diabetes Care , vol.24 , Issue.5 , pp. 886-890
    • Rave, K.1    Heise, T.2    Pfutzner, A.3    Heinemann, L.4    Sawicki, P.T.5
  • 85
    • 84866673865 scopus 로고    scopus 로고
    • A randomized trial of two weight-based doses of insulin glargine and glulisine in hospitalized subjects with type 2 diabetes and renal insufficiency
    • D. Baldwin, J. Zander, and C. Munoz et al. A randomized trial of two weight-based doses of insulin glargine and glulisine in hospitalized subjects with type 2 diabetes and renal insufficiency Diabetes Care 35 10 2012 1970 1974
    • (2012) Diabetes Care , vol.35 , Issue.10 , pp. 1970-1974
    • Baldwin, D.1    Zander, J.2    Munoz, C.3
  • 86
    • 77958160895 scopus 로고    scopus 로고
    • Day-to-day variation of insulin requirements of patients with type 2 diabetes and end-stage renal disease undergoing maintenance hemodialysis
    • E. Sobngwi, S. Enoru, and G. Ashuntantang et al. Day-to-day variation of insulin requirements of patients with type 2 diabetes and end-stage renal disease undergoing maintenance hemodialysis Diabetes Care 33 7 2010 1409 1412
    • (2010) Diabetes Care , vol.33 , Issue.7 , pp. 1409-1412
    • Sobngwi, E.1    Enoru, S.2    Ashuntantang, G.3
  • 87
    • 0032792964 scopus 로고    scopus 로고
    • Pharmacokinetics and pharmacodynamics of insulin Lispro compared with regular insulin in haemodialysis patients with diabetes mellitus
    • U. Aisenpreis, A. Pfutzner, M. Giehl, F. Keller, and P.M. Jehle Pharmacokinetics and pharmacodynamics of insulin lispro compared with regular insulin in haemodialysis patients with diabetes mellitus Nephrol Dial Transplant 14 suppl 4 1999 5 6 (Pubitemid 29358840)
    • (1999) Nephrology Dialysis Transplantation , vol.14 , Issue.SUPPL. 4 , pp. 5-6
    • Aisenpreis, U.1    Pfutzner, A.2    Giehl, M.3    Keller, F.4    Jehle, P.M.5
  • 89
    • 27444437085 scopus 로고    scopus 로고
    • Pharmacokinetics of insulin aspart in obesity, renal impairment, or hepatic impairment
    • DOI 10.1111/j.1365-2125.2005.02476.x
    • G. Holmes, L. Galitz, P. Hu, and W. Lyness Pharmacokinetics of insulin aspart in obesity, renal impairment, or hepatic impairment Br J Clin Pharmacol 60 5 2005 469 476 (Pubitemid 41532446)
    • (2005) British Journal of Clinical Pharmacology , vol.60 , Issue.5 , pp. 469-476
    • Holmes, G.1    Galitz, L.2    Hu, P.3    Lyness, W.4
  • 90
    • 60449089649 scopus 로고    scopus 로고
    • Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes
    • D.M. Nathan, J.B. Buse, and M.B. Davidson et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care 32 1 2009 193 203
    • (2009) Diabetes Care , vol.32 , Issue.1 , pp. 193-203
    • Nathan, D.M.1    Buse, J.B.2    Davidson, M.B.3
  • 91
    • 75549091263 scopus 로고    scopus 로고
    • Statement by an American Association of Clinical Endocrinologists/ American College of Endocrinology consensus panel on type 2 diabetes mellitus: An algorithm for glycemic control
    • H.W. Rodbard, P.S. Jellinger, and J.A. Davidson et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control Endocr Pract 15 6 2009 540 559
    • (2009) Endocr Pract , vol.15 , Issue.6 , pp. 540-559
    • Rodbard, H.W.1    Jellinger, P.S.2    Davidson, J.A.3
  • 92
    • 84856740961 scopus 로고    scopus 로고
    • Oral pharmacologic treatment of type 2 diabetes mellitus: A clinical practice guideline from the American College of Physicians
    • A. Qaseem, L.L. Humphrey, D.E. Sweet, M. Starkey, and P. Shekelle Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians Ann Intern Med 156 3 2012 218 231
    • (2012) Ann Intern Med , vol.156 , Issue.3 , pp. 218-231
    • Qaseem, A.1    Humphrey, L.L.2    Sweet, D.E.3    Starkey, M.4    Shekelle, P.5
  • 93
    • 84855286477 scopus 로고    scopus 로고
    • Evaluation of guideline recommendations on oral medications for type 2 diabetes mellitus: A systematic review
    • W.L. Bennett, O.A. Odelola, and L.M. Wilson et al. Evaluation of guideline recommendations on oral medications for type 2 diabetes mellitus: a systematic review Ann Intern Med 156 1, pt 1 2012 27 36
    • (2012) Ann Intern Med , vol.156 , Issue.1 PART 1 , pp. 27-36
    • Bennett, W.L.1    Odelola, O.A.2    Wilson, L.M.3
  • 94
    • 0038729523 scopus 로고    scopus 로고
    • Characteristics and time course of severe glimepiride- versus glibenclamide-induced hypoglycaemia
    • A. Holstein, A. Plaschke, C. Hammer, and E.H. Egberts Characteristics and time course of severe glimepiride- versus glibenclamide-induced hypoglycaemia Eur J Clin Pharmacol 59 2 2003 91 97 (Pubitemid 36793719)
    • (2003) European Journal of Clinical Pharmacology , vol.59 , Issue.2 , pp. 91-97
    • Holstein, A.1    Plaschke, A.2    Hammer, C.3    Egberts, E.-H.4
  • 95
    • 84857192367 scopus 로고    scopus 로고
    • Characteristics of patients with sulphonurea-induced hypoglycemia
    • Y.D. Schejter, E. Turvall, and Z. Ackerman Characteristics of patients with sulphonurea-induced hypoglycemia J Am Med Dir Assoc 13 3 2012 234 238
    • (2012) J Am Med Dir Assoc , vol.13 , Issue.3 , pp. 234-238
    • Schejter, Y.D.1    Turvall, E.2    Ackerman, Z.3
  • 96
    • 0029857682 scopus 로고    scopus 로고
    • Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment
    • DOI 10.1007/s001250050624
    • B. Rosenkranz, V. Profozic, Z. Metelko, V. Mrzljak, C. Lange, and V. Malerczyk Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment Diabetologia 39 12 1996 1617 1624 (Pubitemid 26397377)
    • (1996) Diabetologia , vol.39 , Issue.12 , pp. 1617-1624
    • Rosenkranz, B.1    Profozic, V.2    Metelko, Z.3    Mrzljak, V.4    Lange, C.5    Malerczyk, V.6
  • 98
    • 67651119920 scopus 로고    scopus 로고
    • Prescribing metformin in type 2 diabetes with a contraindication: Prevalence and outcome
    • J. Pongwecharak, N. Tengmeesri, N. Malanusorn, M. Panthong, and N. Pawangkapin Prescribing metformin in type 2 diabetes with a contraindication: prevalence and outcome Pharm World Sci 31 4 2009 481 486
    • (2009) Pharm World Sci , vol.31 , Issue.4 , pp. 481-486
    • Pongwecharak, J.1    Tengmeesri, N.2    Malanusorn, N.3    Panthong, M.4    Pawangkapin, N.5
  • 99
    • 77953634420 scopus 로고    scopus 로고
    • Clinical effectiveness and safety evaluation of long-term pioglitazone treatment for erythropoietin responsiveness and insulin resistance in type 2 diabetic patients on hemodialysis
    • M. Abe, K. Okada, T. Maruyama, N. Maruyama, M. Soma, and K. Matsumoto Clinical effectiveness and safety evaluation of long-term pioglitazone treatment for erythropoietin responsiveness and insulin resistance in type 2 diabetic patients on hemodialysis Expert Opin Pharmacother 11 10 2010 1611 1620
    • (2010) Expert Opin Pharmacother , vol.11 , Issue.10 , pp. 1611-1620
    • Abe, M.1    Okada, K.2    Maruyama, T.3    Maruyama, N.4    Soma, M.5    Matsumoto, K.6
  • 100
    • 0344233280 scopus 로고    scopus 로고
    • Effects of Rosiglitazone Maleate When Added to a Sulfonylurea Regimen in Patients with Type 2 Diabetes Mellitus and Mild to Moderate Renal Impairment: A Post Hoc Analysis
    • DOI 10.1016/S0149-2918(03)80331-4
    • A. Agrawal, M.C. Sautter, and N.P. Jones Effects of rosiglitazone maleate when added to a sulfonylurea regimen in patients with type 2 diabetes mellitus and mild to moderate renal impairment: a post hoc analysis Clin Ther 25 11 2003 2754 2764 (Pubitemid 37510588)
    • (2003) Clinical Therapeutics , vol.25 , Issue.11 , pp. 2754-2764
    • Agrawal, A.1    Sautter, M.C.2    Jones, N.P.3
  • 101
    • 33846003119 scopus 로고    scopus 로고
    • Rosiglitazone in diabetes control in hemodialysis patients with and without viral hepatitis infection: Effectiveness and side effects
    • C.K. Chiang, T.I. Ho, and Y.S. Peng et al. Rosiglitazone in diabetes control in hemodialysis patients with and without viral hepatitis infection: effectiveness and side effects Diabetes Care 30 1 2007 3 7
    • (2007) Diabetes Care , vol.30 , Issue.1 , pp. 3-7
    • Chiang, C.K.1    Ho, T.I.2    Peng, Y.S.3
  • 104
    • 34250212715 scopus 로고    scopus 로고
    • Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes
    • S.E. Nissen, and K. Wolski Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes N Engl J Med 356 24 2007 2457 2471 (Pubitemid 46919772)
    • (2007) New England Journal of Medicine , vol.356 , Issue.24 , pp. 2457-2471
    • Nissen, S.E.1    Wolski, K.2
  • 105
    • 65649089128 scopus 로고    scopus 로고
    • Rosiglitazone is associated with mortality in chronic hemodialysis patients
    • S.P. Ramirez, J.M. Albert, and M.J. Blayney et al. Rosiglitazone is associated with mortality in chronic hemodialysis patients J Am Soc Nephrol 20 5 2009 1094 1101
    • (2009) J Am Soc Nephrol , vol.20 , Issue.5 , pp. 1094-1101
    • Ramirez, S.P.1    Albert, J.M.2    Blayney, M.J.3
  • 106
    • 79956217900 scopus 로고    scopus 로고
    • Risk of bladder cancer among diabetic patients treated with pioglitazone: Interim report of a longitudinal cohort study
    • J.D. Lewis, A. Ferrara, and T. Peng et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study Diabetes Care 34 4 2011 916 922
    • (2011) Diabetes Care , vol.34 , Issue.4 , pp. 916-922
    • Lewis, J.D.1    Ferrara, A.2    Peng, T.3
  • 108
    • 80052530183 scopus 로고    scopus 로고
    • Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin(*)
    • U. Graefe-Mody, C. Friedrich, and A. Port et al. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin(*) Diabetes Obes Metab 13 10 2011 939 946
    • (2011) Diabetes Obes Metab , vol.13 , Issue.10 , pp. 939-946
    • Graefe-Mody, U.1    Friedrich, C.2    Port, A.3
  • 109
    • 80052551137 scopus 로고    scopus 로고
    • Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: A prospective 24-week randomized placebo-controlled trial
    • V. Lukashevich, A. Schweizer, Q. Shao, P.H. Groop, and W. Kothny Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial Diabetes Obes Metab 13 10 2011 947 954
    • (2011) Diabetes Obes Metab , vol.13 , Issue.10 , pp. 947-954
    • Lukashevich, V.1    Schweizer, A.2    Shao, Q.3    Groop, P.H.4    Kothny, W.5
  • 110
    • 81755181497 scopus 로고    scopus 로고
    • Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: A randomised controlled 52-week efficacy and safety study
    • M. Nowicki, I. Rychlik, and H. Haller et al. Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study Int J Clin Pract 65 12 2011 1230 1239
    • (2011) Int J Clin Pract , vol.65 , Issue.12 , pp. 1230-1239
    • Nowicki, M.1    Rychlik, I.2    Haller, H.3
  • 111
    • 79955048927 scopus 로고    scopus 로고
    • Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment
    • M. Nowicki, I. Rychlik, H. Haller, M.L. Warren, L. Suchower, and I. Gause-Nilsson Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment Diabetes Obes Metab 13 6 2011 523 532
    • (2011) Diabetes Obes Metab , vol.13 , Issue.6 , pp. 523-532
    • Nowicki, M.1    Rychlik, I.2    Haller, H.3    Warren, M.L.4    Suchower, L.5    Gause-Nilsson, I.6
  • 112
    • 67649666737 scopus 로고    scopus 로고
    • Liraglutide once a day versus exenatide twice a day for type 2 diabetes: A 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
    • J.B. Buse, J. Rosenstock, and G. Sesti et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6) Lancet 374 9683 2009 39 47
    • (2009) Lancet , vol.374 , Issue.9683 , pp. 39-47
    • Buse, J.B.1    Rosenstock, J.2    Sesti, G.3
  • 113
    • 84872084453 scopus 로고    scopus 로고
    • Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): A randomised, open-label study
    • J.B. Buse, M. Nauck, and T. Forst et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study Lancet 381 9861 2013 117 124
    • (2013) Lancet , vol.381 , Issue.9861 , pp. 117-124
    • Buse, J.B.1    Nauck, M.2    Forst, T.3
  • 114
    • 70849096647 scopus 로고    scopus 로고
    • Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide
    • L.V. Jacobsen, C. Hindsberger, R. Robson, and M. Zdravkovic Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide Br J Clin Pharmacol 68 6 2009 898 905
    • (2009) Br J Clin Pharmacol , vol.68 , Issue.6 , pp. 898-905
    • Jacobsen, L.V.1    Hindsberger, C.2    Robson, R.3    Zdravkovic, M.4
  • 117
    • 78349307376 scopus 로고    scopus 로고
    • Acute renal failure when exenatide is co-administered with diuretics and angiotensin II blockers
    • A. Lopez-Ruiz, C. del Peso-Gilsanz, and A. Meoro-Aviles et al. Acute renal failure when exenatide is co-administered with diuretics and angiotensin II blockers Pharm World Sci 32 5 2010 559 561
    • (2010) Pharm World Sci , vol.32 , Issue.5 , pp. 559-561
    • Lopez-Ruiz, A.1    Del Peso-Gilsanz, C.2    Meoro-Aviles, A.3
  • 118
    • 84862777558 scopus 로고    scopus 로고
    • Exenatide and sitagliptin are not associated with increased risk of acute renal failure: A retrospective claims analysis
    • M. Pendergrass, C. Fenton, S.M. Haffner, and W. Chen Exenatide and sitagliptin are not associated with increased risk of acute renal failure: a retrospective claims analysis Diabetes Obes Metab 14 7 2012 596 600
    • (2012) Diabetes Obes Metab , vol.14 , Issue.7 , pp. 596-600
    • Pendergrass, M.1    Fenton, C.2    Haffner, S.M.3    Chen, W.4
  • 119
    • 84876063836 scopus 로고    scopus 로고
    • Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: A population-based matched case-control study
    • S. Singh, H.Y. Chang, T.M. Richards, J.P. Weiner, J.M. Clark, and J.B. Segal Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study JAMA Intern Med 173 7 2013 534 539
    • (2013) JAMA Intern Med , vol.173 , Issue.7 , pp. 534-539
    • Singh, S.1    Chang, H.Y.2    Richards, T.M.3    Weiner, J.P.4    Clark, J.M.5    Segal, J.B.6
  • 120
    • 79951704452 scopus 로고    scopus 로고
    • Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: A retrospective observational pharmacy claims analysis
    • R. Garg, W. Chen, and M. Pendergrass Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis Diabetes Care 33 11 2010 2349 2354
    • (2010) Diabetes Care , vol.33 , Issue.11 , pp. 2349-2354
    • Garg, R.1    Chen, W.2    Pendergrass, M.3
  • 121
    • 67649304917 scopus 로고    scopus 로고
    • Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide
    • D.D. Dore, J.D. Seeger, and K. Arnold Chan Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide Curr Med Res Opin 25 4 2009 1019 1027
    • (2009) Curr Med Res Opin , vol.25 , Issue.4 , pp. 1019-1027
    • Dore, D.D.1    Seeger, J.D.2    Arnold Chan, K.3
  • 122
    • 84860567470 scopus 로고    scopus 로고
    • Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model
    • B. Gier, A.V. Matveyenko, D. Kirakossian, D. Dawson, S.M. Dry, and P.C. Butler Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model Diabetes 61 5 2012 1250 1262
    • (2012) Diabetes , vol.61 , Issue.5 , pp. 1250-1262
    • Gier, B.1    Matveyenko, A.V.2    Kirakossian, D.3    Dawson, D.4    Dry, S.M.5    Butler, P.C.6
  • 123
    • 77950228684 scopus 로고    scopus 로고
    • Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation
    • L. Bjerre Knudsen, L.W. Madsen, and S. Andersen et al. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation Endocrinology 151 4 2010 1473 1486
    • (2010) Endocrinology , vol.151 , Issue.4 , pp. 1473-1486
    • Bjerre Knudsen, L.1    Madsen, L.W.2    Andersen, S.3
  • 124
    • 79952284556 scopus 로고    scopus 로고
    • GLP-1 and calcitonin concentration in humans: Lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide
    • L. Hegedus, A.C. Moses, M. Zdravkovic, T. Le Thi, and G.H. Daniels GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide J Clin Endocrinol Metab 96 3 2011 853 860
    • (2011) J Clin Endocrinol Metab , vol.96 , Issue.3 , pp. 853-860
    • Hegedus, L.1    Moses, A.C.2    Zdravkovic, M.3    Le Thi, T.4    Daniels, G.H.5
  • 127
    • 0027724063 scopus 로고
    • Acarbose. An update of its pharmacology and therapeutic use in diabetes mellitus
    • J.A. Balfour, and D. McTavish Acarbose. An update of its pharmacology and therapeutic use in diabetes mellitus Drugs 46 6 1993 1025 1054 (Pubitemid 24016644)
    • (1993) Drugs , vol.46 , Issue.6 , pp. 1025-1054
    • Balfour, J.A.1    McTavish, D.2
  • 128
    • 32344433818 scopus 로고    scopus 로고
    • Hepatotoxicity associated with acarbose therapy
    • S.H. Hsiao, L.H. Liao, P.N. Cheng, and T.J. Wu Hepatotoxicity associated with acarbose therapy Ann Pharmacother 40 1 2006 151 154
    • (2006) Ann Pharmacother , vol.40 , Issue.1 , pp. 151-154
    • Hsiao, S.H.1    Liao, L.H.2    Cheng, P.N.3    Wu, T.J.4
  • 129
    • 33947120281 scopus 로고    scopus 로고
    • Results of the glucose-lowering effect of WelChol study (GLOWS): A randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes
    • DOI 10.1016/j.clinthera.2007.01.003, PII S0149291807000173
    • F.J. Zieve, M.F. Kalin, S.L. Schwartz, M.R. Jones, and W.L. Bailey Results of the Glucose-Lowering Effect of WelChol Study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes Clin Ther 29 1 2007 74 83 (Pubitemid 46414026)
    • (2007) Clinical Therapeutics , vol.29 , Issue.1 , pp. 74-83
    • Zieve, F.J.1    Kalin, M.F.2    Schwartz, S.L.3    Jones, M.R.4    Bailey, W.L.5
  • 130
    • 78049465403 scopus 로고    scopus 로고
    • Bromocriptine mesylate for glycemic management in type 2 diabetes mellitus
    • J.L. Kerr, E.M. Timpe, and K.A. Petkewicz Bromocriptine mesylate for glycemic management in type 2 diabetes mellitus Ann Pharmacother 44 11 2010 1777 1785
    • (2010) Ann Pharmacother , vol.44 , Issue.11 , pp. 1777-1785
    • Kerr, J.L.1    Timpe, E.M.2    Petkewicz, K.A.3
  • 131
    • 77958179761 scopus 로고    scopus 로고
    • Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes
    • J.M. Gaziano, A.H. Cincotta, and C.M. O'Connor et al. Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes Diabetes Care 33 7 2010 1503 1508
    • (2010) Diabetes Care , vol.33 , Issue.7 , pp. 1503-1508
    • Gaziano, J.M.1    Cincotta, A.H.2    O'Connor, C.M.3
  • 132
    • 69549130787 scopus 로고    scopus 로고
    • Randomized comparison of pramlintide or mealtime insulin added to basal insulin treatment for patients with type 2 diabetes
    • M. Riddle, R. Pencek, S. Charenkavanich, K. Lutz, K. Wilhelm, and L. Porter Randomized comparison of pramlintide or mealtime insulin added to basal insulin treatment for patients with type 2 diabetes Diabetes Care 32 9 2009 1577 1582
    • (2009) Diabetes Care , vol.32 , Issue.9 , pp. 1577-1582
    • Riddle, M.1    Pencek, R.2    Charenkavanich, S.3    Lutz, K.4    Wilhelm, K.5    Porter, L.6
  • 133
    • 84862777052 scopus 로고    scopus 로고
    • Comparative effectiveness of incident oral antidiabetic drugs on kidney function
    • A.M. Hung, C.L. Roumie, and R.A. Greevy et al. Comparative effectiveness of incident oral antidiabetic drugs on kidney function Kidney Int 81 7 2012 698 706
    • (2012) Kidney Int , vol.81 , Issue.7 , pp. 698-706
    • Hung, A.M.1    Roumie, C.L.2    Greevy, R.A.3
  • 134
    • 52049120372 scopus 로고    scopus 로고
    • Glycemic control in diabetic CKD patients: Where do we stand?
    • C.P. Kovesdy, K. Sharma, and K. Kalantar-Zadeh Glycemic control in diabetic CKD patients: where do we stand? Am J Kidney Dis 52 2008 766 777
    • (2008) Am J Kidney Dis , vol.52 , pp. 766-777
    • Kovesdy, C.P.1    Sharma, K.2    Kalantar-Zadeh, K.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.